AIM ImmunoTech (AIM) inks $1.5M manufacturing pact for Ampligen
Rhea-AI Filing Summary
AIM ImmunoTech Inc. entered into a Proposal Agreement with Sterling Pharma Solutions on July 31, 2026. Under this arrangement, Sterling will manufacture additional batches of the polynucleotide drug substances PolyI and Poly C12U and transfer associated test methods at its Dudley, UK facility. These materials serve as polymer precursors for producing the drug Ampligen.
The estimated cost to AIM is approximately $1.5 million, payable over 12 months. AIM plans to use the manufactured product in ongoing and future clinical trials, including potentially a Phase 3 clinical trial for metastatic pancreatic cancer.
AIM also outlined timing requirements for stockholders wishing to nominate directors or bring other business at the 2026 annual meeting outside Rule 14a-8. Notices must be received between August 18, 2026 and 5:00 p.m. local time on September 17, 2026, with a separate Rule 14a-19 universal proxy notice due by October 19, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 5.08, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 5.08
Shareholder Director Nominations
Governance
Shareholder nominations for board of directors under proxy access rules. Rarely used -- the underlying SEC rule was vacated.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Proposal Agreement estimated cost: $1.5 million
Payment period: 12 months
Nomination notice opening date: August 18, 2026
+3 more
6 metrics
Proposal Agreement estimated cost
$1.5 million
Estimated cost to AIM under the Proposal Agreement, payable over 12 months
Payment period
12 months
Period over which the approximately $1.5 million is to be paid
Nomination notice opening date
August 18, 2026
Earliest date stockholder notices for the 2026 annual meeting may be received
Nomination notice deadline
5:00 p.m. local time on September 17, 2026
Latest time for stockholder notices for the 2026 annual meeting
Universal proxy notice deadline
October 19, 2026
Deadline to provide Rule 14a-19 notice for alternative director nominees
Agreement date
July 31, 2026
Date AIM and Sterling Pharma Solutions entered into the Proposal Agreement
Key Terms
Material Definitive Agreement, Master Service Agreement, Quality Agreement, universal proxy rules, +2 more
6 terms
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Master Service Agreement regulatory
"related to the Master Service Agreement and a Quality Agreement entered into"
A master service agreement (MSA) is a framework contract that sets standard terms—such as pricing rules, responsibilities, liability limits and dispute processes—for all future work between two parties, so individual projects only need a short statement of work. For investors, an MSA matters because it creates predictable revenue procedures, reduces deal-making friction, clarifies risk exposure and can speed sales cycles, improving the company’s ability to win and deliver repeat business.
Quality Agreement regulatory
"related to the Master Service Agreement and a Quality Agreement entered into"
universal proxy rules regulatory
"In addition to satisfying the foregoing requirements, to comply with the universal proxy rules"
Universal proxy rules require that when shareholders vote to elect directors in a contested election, the proxy card mailed to investors can include candidates nominated by both the company and dissident shareholders, letting investors mix and match their choices on a single ballot. This matters to investors because it makes their vote more flexible and easier to use, like replacing separate lists with one common ballot, which can influence who controls the board and the company’s future direction.
Rule 14a-19 regulatory
"must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act"
Rule 14a-19 is a U.S. Securities and Exchange Commission rule that governs how independent proxy advisory firms produce and distribute voting recommendations for shareholders. It requires these advisers to provide companies with notice of their recommendations and a chance to respond, and to disclose certain conflicts; think of it as a referee ensuring both sides see a game plan before fans cast votes. Investors care because proxy advisers influence voting outcomes and corporate governance, so the rule affects transparency, potential bias, and the reliability of guidance that many investors rely on when voting shares.
metastatic pancreatic cancer medical
"including potentially a Phase 3 clinical trial for metastatic pancreatic cancer."
A serious form of cancer that began in the pancreas and has spread to other parts of the body, such as the liver or lungs; think of it like a fire that started in one room and has moved through the house. It matters to investors because metastatic disease usually signals advanced illness with limited treatment options, influencing the commercial prospects of therapies, clinical trial success, healthcare costs, and the financial outlook for companies working on diagnostics or treatments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What material agreement did AIM (AIM) enter into on July 31, 2026?
AIM ImmunoTech entered a Proposal Agreement with Sterling Pharma Solutions. Sterling will manufacture PolyI and Poly C12U and transfer test methods at its Dudley, UK site to support Ampligen production for clinical trials.
What is the value and duration of AIM’s new manufacturing arrangement (AIM)?
The estimated cost to AIM under the Proposal Agreement is approximately $1.5 million, payable over a period of 12 months. Payment timing and milestones are described in more detail in the Proposal Agreement itself.
How will AIM (AIM) use the products from the Sterling Pharma Proposal Agreement?
AIM anticipates using the manufactured PolyI and Poly C12U to produce Ampligen for ongoing and future clinical trials, including potentially a Phase 3 metastatic pancreatic cancer trial, subject to clinical and regulatory progress.
What are the 2026 director nomination deadlines for AIM (AIM) stockholders?
To nominate directors or bring other business at the 2026 annual meeting outside Rule 14a-8, stockholders must deliver notice between August 18, 2026 and 5:00 p.m. local time on September 17, 2026 to AIM’s Secretary.
What is the universal proxy notice deadline for AIM (AIM) stockholders?
Stockholders planning to solicit proxies for director nominees other than AIM’s nominees must provide a Rule 14a-19 universal proxy notice by October 19, 2026. The notice must include the information specified by Rule 14a-19 under the Exchange Act.
Which drug substances are covered by AIM’s (AIM) new Proposal Agreement?
The Proposal Agreement covers manufacturing further batches of PolyI and Poly C12U and transferring associated test methods. These are polynucleotide drug substances used as polymer precursors in the manufacture of the drug Ampligen.